# Anthem


## Posts

- [Sample Blog Post](https://anthembio.com/sample-blog-post/): Embarking on a rebranding journey for your business is an exciting yet challenging endeavor.

## Pages

- [Policy on materiality of RPT and on dealing with RPT](https://anthembio.com/policy-on-materiality-of-rpt-and-on-dealing-with-rpt-2/): The Board of Directors (“Board”) of Anthem Biosciences Limited (“Company”) has adopted the following policy on materiality of related party transactions and on dealing with related party transactions (“Policy”) with regard to the Related Party Transactions (“RPT”) in line with the requirements of Companies Act, 2013 (“Act”) and Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) as may be applicable to the Company.
- [Policy for inquiry in case for leak of UPSI](https://anthembio.com/policy-for-inquiry-in-case-for-leak-of-upsi-3/): In accordance with Regulation 8 read with Schedule A of the Securities and Exchange Board of India (SEBI) (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations) as amended requires every listed company to formulate a Code of Practices and Procedures for Fair Disclosure of UPSI.
- [Environment, Social & Governance and Climate Change Policy](https://anthembio.com/environment-social-governance-and-climate-change-policy-2/): ANTHEM BIOSCIENCES PRIVATE LIMITED (hereinafter referred to as “Anthem”/“Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) providing discovery biology services, synthetic chemical research and analysis, chemical synthesis, manufacturing of specialty chemical products, analytical method development, and related services.
- [Contact Us](https://anthembio.com/contact-us/): Feel free to reach out to us using the options below, and our dedicated team will respond to your inquiries promptly.
- [Industries Catered](https://anthembio.com/industries-catered/): Pharmaceuticals Nutrition (Human Health) Nutrition (Animal Health) Industrial (Textiles / Pulp-paper/Detergent/Leather etc.)
- [Privacy Policy](https://anthembio.com/privacy-policy/): This Privacy Policy describes Our policies and procedures on the collection, use and disclosure of Your information when You use the Service and tells You about Your privacy rights and how the law protects You.
- [Terms & Conditions](https://anthembio.com/terms-conditions/): Please read these terms and conditions carefully before using Our Service.
- [QA/QC](https://anthembio.com/qa-qc/): Anthem offers a full range of Quality Control (QC) and Quality Assurance (QA) services to ensure pharmaceutical products meet the highest standards of quality, compliance, and regulatory requirements.
- [Flow Chemistry](https://anthembio.com/flow-chemistry/): Precision and Sustainability in Continuous Synthesis Flow chemistry is revolutionizing chemical manufacturing by offering continuous, efficient, and scalable reactions with enhanced safety.
- [Financial Information](https://anthembio.com/financial-information/)
- [Reports](https://anthembio.com/reports/)
- [Investors AV Disclaimer (RHP)](https://anthembio.com/investors-av-disclaimer-rhp/): All persons residing outside of the United States who wish to access this video should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this video or require registration or approval for any acquisition of securities by them.
- [Biotransformation Enzymes](https://anthembio.com/biotransformation-enzymes/): Biotransformation enzymes are critical enzymes that aid in the conversion of various substances within the body, playing a vital role in drug metabolism.
- [Oligonucleotides](https://anthembio.com/oligonucleotides/): Anthem provides integrated solutions in custom oligonucleotides and phosphoramidite building blocks for drug discovery, diagnostics, and research.
- [Policy on materiality of RPT and on dealing with RPT](https://anthembio.com/policy-on-materiality-of-rpt-and-on-dealing-with-rpt/): The Board of Directors (“Board”) of Anthem Biosciences Limited (“Company”) has adopted the following policy on materiality of related party transactions and on dealing with related party transactions (“Policy”) with regard to the Related Party Transactions (“RPT”) in line with the requirements of Companies Act, 2013 (“Act”) and Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) as may be applicable to the Company.
- [Policy for inquiry in case for leak of UPSI](https://anthembio.com/policy-for-inquiry-in-case-for-leak-of-upsi/): Regulation 9A (5) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 (“SEBI PIT Regulations”) mandates every listed company to formulate a written policy and procedure for inquiry in case of leak of Unpublished Price Sensitive Information (‘UPSI’) or suspected leak of UPSI (the ‘Policy’) and initiate appropriate inquiries on becoming aware of leak or suspected leak of UPSI and inform the Securities Exchange Board of India (SEBI) and the Stock Exchanges promptly of such leaks, inquiries and results of such inquiries.
- [Policy for determination of material events and information under SEBI Listing Regulations](https://anthembio.com/policy-for-determination-of-material-events-and-information-under-sebi-listing-regulations/): This document has been formulated to define the policy for identification of (i) outstanding material litigation (in addition to all criminal proceedings, actions by statutory/ regulatory authorities and taxation matters) involving Anthem Biosciences Limited (the “Company”), its Subsidiary, its Directors and its Promoters, as applicable; (ii) companies to be considered as Group Companies; and (iii) the material creditors of the Company (together, the “Policy”), in terms of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”), in relation to the proposed initial public offering of equity shares by the Company (“Offer”).
- [Policy on Determination of Materiality for Disclosure of Events or Information](https://anthembio.com/policy-on-determination-of-materiality-for-disclosure-of-events-or-information/): The Policy for determining ‘materiality’ of events/information (“the Policy”) has been framed in accordance with the provisions of Regulation 30(4)(ii) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as amended from time to time and the policy need to be approved by the Board of Directors of Anthem Biosciences Limited.
- [Anthem - Home](https://anthembio.com/): Integrated CRDMO services across discovery, development and commercial manufacturing for small molecules, peptides, lipids, oligos, high-potent APIs and large molecules.
- [Biologics Development](https://anthembio.com/biologics-development/): Anthem Biosciences offers integrated services to support your biologics pipeline—from cell line development through upstream and downstream process optimization to analytical characterization—ensuring your product meets quality and regulatory standards for clinical and commercial success.
- [GMP Manufacturing](https://anthembio.com/large-molecules/gmp-manufacturing/): Anthem Biosciences operates state-of-the-art GMP facilities designed specifically for the complex requirements of biologics, meeting stringent regulatory guidelines from agencies such as the FDA, EMA, and WHO.
- [Pre-Clinical Evaluation](https://anthembio.com/preclinical-evaluation/): Preclinical evaluation is a vital phase in the development of large molecule therapeutics, providing essential data on safety, efficacy, pharmacokinetics and toxicology before human clinical trials.
- [New Age Chemistry](https://anthembio.com/new-age-chemistry/): Anthem’s transformative approach focuses on innovative, sustainable, and efficient methodologies that redefine chemical processes while minimizing environmental impact and boosting productivity.
- [Discovery](https://anthembio.com/discovery/): At Anthem Biosciences, we offer comprehensive small molecule drug discovery services to accelerate your journey from initial concept to preclinical candidate.
- [Clinical & Commercial](https://anthembio.com/large-molecules/clinical-commercial/): The clinical and commercial phases of large molecule drug development demand highly controlled, scalable and compliant manufacturing processes.
- [Discovery & Pre-Clinical](https://anthembio.com/large-molecules/discovery-pre-clinical-2/): The discovery and preclinical phase is critical in the lifecycle of large molecule therapeutics, laying the foundation for successful clinical development and commercialization.
- [Cell Line Development](https://anthembio.com/cell-line-development-2/): Cell line development (CLD) is a critical step in the development of biologics, shaping the efficiency, yield and quality of therapeutic proteins and antibodies.
- [Antibody Generation](https://anthembio.com/antibody-generation/): Antibodies are critical tools in modern medicine, serving as targeted therapeutics, diagnostic reagents and research tools.
- [GMP Manufacturing](https://anthembio.com/small-molecules/gmp-manufacturing/): Anthem specializes in the design, development and manufacturing of APIs and Advanced intermediates, providing comprehensive support from clinical development to commercial-scale production.
- [Analytical Services](https://anthembio.com/analytical-services/): We deliver precise and reliable analytical services, ensuring your products meet stringent quality and compliance standards.
- [Synthetic & Medicinal Chemistry](https://anthembio.com/synthetic-medicinal-chemistry/): At Anthem, our team works to optimize molecules and understand their effects.
- [Integrated Drug Discovery](https://anthembio.com/integrated-drug-discovery/): Our team of over 2,000 dedicated researchers and scientists delivers exceptional quality in drug discovery, development, and preclinical testing.
- [Discovery Biology](https://anthembio.com/discovery-biology/): We provide comprehensive Discovery Biology services to drive your drug development programs, leveraging state-of-the-art technologies and robust in vitro and in vivo assays to provide critical insights into the biological activity, safety, and efficacy of your drug candidates.
- [Pincer Catalysis](https://anthembio.com/pincer-catalysis/): Pincer Catalysis offers a powerful toolbox for achieving efficient and sustainable transformations in small molecule synthesis.
- [Micellar Chemistry](https://anthembio.com/micellar-chemistry/): Micellar Chemistry harnesses the power of self-assembling amphiphilic molecules in aqueous solutions to create nano-reactors that enhance reaction rates, selectivity, and sustainability.
- [Green Chemistry](https://anthembio.com/green-chemistry/): The future of small molecule development lies in sustainability, at Anthem we are committed to minimizing environmental impact, reducing waste, and using safer, more sustainable alternatives in every aspect of our operations.
- [Biocatalysis](https://anthembio.com/biocatalysis/): Use of biological catalysts such as enzymes or whole cells to perform chemical transformations enables the synthesis of complex molecules with greater precision and under milder conditions.
- [Infrastructure](https://anthembio.com/infrastructure/): Anthem operates a network of state-of-the-art, automated manufacturing facilities in Bangalore, India, delivering end-to-end development and scalable production across multiple advanced modalities.
- [Peptides](https://anthembio.com/peptides-2/): At Anthem, we specialize in the synthesis of high-quality peptides of up to 40 amino acids, catering to therapeutic and research applications.
- [HPAPI](https://anthembio.com/hpapi/): Anthem has the capability to handle toxicity levels up to OEB 5, our infrastructure and expertise enable the synthesis of highly potent compounds for innovative targeted therapies.
- [Lipids](https://anthembio.com/lipids/): From lipid nanoparticles (LNPs) for mRNAi and gene therapies to advanced lipid formulations for vaccines, Anthem specialize in the development and manufacturing of lipids that power the next generation of drug delivery systems and therapeutics.
- [Careers](https://anthembio.com/careers/): We are not just following the science, we are leading it.
- [Our Journey](https://anthembio.com/our-journey/): For decades, Anthem has been built on a simple, powerful belief: science can conquer the greatest health challenges.
- [Operations Consultant Vacancy Page](https://anthembio.com/operations-consultant/): We are looking for self driven individuals who are entrepreneurial in nature and are open to join start up organizations.
- [Events](https://anthembio.com/events/): Progress in health is a shared endeavor. Our events bring together the brightest minds in science, medicine, and policy to collaborate, debate and discover.
- [Blogs](https://anthembio.com/blogs/): At Anthem, we are pioneering the next generation of medicines.
- [News](https://anthembio.com/news/)
- [Antibody-Drug Conjugates (ADCs)](https://anthembio.com/antibody-drug-conjugates-adcs/): Engineered to deliver highly targeted treatments, Antibody-Drug Conjugates (ADCs) are at the forefront of innovative cancer therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs.
- [Discovery & Pre-Clinical](https://anthembio.com/discovery-pre-clinical/): The discovery and preclinical phase is critical in the lifecycle of large molecule therapeutics, laying the foundation for successful clinical development and commercialization.
- [Protein Sciences & Molecular Biology](https://anthembio.com/protein-sciences-molecular-biology/): Proteins are fundamental biomolecules that perform diverse and critical functions in living organisms, including enzymatic catalysis, cellular signaling, immune responses and structural support.
- [Small Molecules](https://anthembio.com/small-molecules/): We specialize in providing comprehensive small molecule drug development services.
- [Conflict of Interest Policy](https://anthembio.com/conflict-of-interest-policy/): ANTHEM BIOSCIENCES PRIVATE LIMITED (hereinafter referred to as “Anthem”/“Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) providing discovery biology services, synthetic chemical research and analysis, chemical synthesis, manufacturing of specialty chemical products, analytical method development, and related services.
- [Anthem Employee Stock Option Plan 2024](https://anthembio.com/anthem-employee-stock-option-plan-2024/): This Employee Stock Option Plan shall be called the ‘Anthem Employee Stock Option Plan 2024’ (hereinafter referred to as “ESOP 2024”/ “Plan”).
- [Plan for orderly succession for appointment of directors and senior management](https://anthembio.com/plan-for-orderly-succession-for-appointment-of-directors-and-senior-management/): The Securities and Exchange Board of India (“SEBI”) has mandated the need for a succession policy pursuant to Regulation 17(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“SEBI Listing Regulations”), in order to ensure that interests of investors of Anthem Biosciences Limited (“Company”) does not suffer on account of sudden or unplanned gaps in management of the company.
- [Policy for determining material subsidiaries as per the SEBI Listing Regulations](https://anthembio.com/policy-for-determining-material-subsidiaries-as-per-the-sebi-listing-regulations/): The Policy for determining ‘Material Subsidiaries’ has been framed in accordance with Regulation 16(1)(c) and Regulation 24 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (“SEBI Listing Regulations”) and other applicable provisions (including any statutory enactments / amendments thereof).
- [Dividend Distribution Policy](https://anthembio.com/dividend-distribution-policy/): The Policy's objective is to maintain guidelines for the Board of Directors to follow when declaring or recommending the amount of dividend (interim or final) per share.
- [Risk Management Policy](https://anthembio.com/risk-management-policy/): The Risk Management Committee (RMC) is applicable to the top 1000 listed entities, determined based on market capitalization as at the end of the immediate preceding financial year.
- [Nomination and Remuneration Policy](https://anthembio.com/nomination-and-remuneration-policy/): Pursuant to Section 178(3) of the Companies Act, 2013 (the “Act”) and Regulation 19(4) read with Part D of Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”).
- [Policy on evaluation of the performance of the Board of Directors](https://anthembio.com/policy-on-evaluation-of-the-performance-of-the-board-of-directors/): Given that overseeing the company's performance ranks among the primary duties of the Board of Directors, this policy seeks to implement a structured process for regularly evaluating the Board, its committees, and the performance of individual directors, while also defining the criteria for such evaluations.
- [Probiotics](https://anthembio.com/probiotics/): Probiotics are gut-friendly microbes (bacteria or yeast) that play a pivotal role in balancing the intestinal microbiome in humans and animals.
- [Vitamin Analogues](https://anthembio.com/vitamin-analogues/): Anthem offers a diverse portfolio of vitamin analogues that cater to various therapeutic and nutritional applications.
- [Nutritional Actives](https://anthembio.com/nutritional-actives/): Anthem offers a range of high-quality nutritional actives designed to support health and wellness across multiple domains.
- [Biosimilars](https://anthembio.com/biosimilars/): Anthem specializes in the development and production of biosimilars using cutting-edge technologies across various expression systems.
- [Peptides](https://anthembio.com/peptides/): Anthem offers a range of high-quality peptide APIs designed for various therapeutic applications.
- [Functional Enzymes](https://anthembio.com/functional-enzymes/): Anthem offers a range of high-quality functional enzymes designed to support digestive health and various industrial applications.
- [APIs](https://anthembio.com/apis/): Anthem offers a diverse portfolio of high-quality Active Pharmaceutical Ingredients (APIs) that cater to various therapeutic areas.
- [Fermentation Products](https://anthembio.com/fermentation-products/): We utilize a range of fermentation processes, based on specific conditions and applications of different biologics.
- [Clinical & Commercial](https://anthembio.com/clinical-commercial/): The clinical and commercial phases of large molecule drug development demand highly controlled, scalable and compliant manufacturing processes.
- [Preclinical Evaluation](https://anthembio.com/preclinical-evaluation-draft/): Preclinical evaluation is a vital phase in the development of large molecule therapeutics, providing essential data on safety, efficacy, pharmacokinetics and toxicology before human clinical trials.
- [Code of Practices & Procedures for Fair Disclosure of UPSI](https://anthembio.com/code-of-practices-procedures-for-fair-disclosure-of-upsi/): Regulation 8 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (“SEBI PIT Regulations”), as amended, require every listed company to formulate a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information inter alia containing the principles of fair disclosure as stipulated in the SEBI PIT Regulations.
- [Policy on Preservation of Documents or Archival Policy](https://anthembio.com/policy-on-preservation-of-documents-or-archival-policy/): This Policy has been framed and approved by the Board of Directors of the Anthem Biosciences Limited (the Company) as per the requirement of Regulation 9 and Regulation 30(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- [Prevention of Sexual Harassment at Workplace (POSH) Policy](https://anthembio.com/prevention-of-sexual-harassment-at-workplace-posh-policy/): ANTHEM BIOSCIENCES LIMITED (hereinafter referred to as “Anthem”/“Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) providing discovery biology services, synthetic chemical research and analysis, chemical synthesis, manufacturing of specialty chemical products, analytical method development, and related services.
- [Anti-Bribery & Anti-Corruption Policy](https://anthembio.com/anti-bribery-anti-corruption-policy/): ANTHEM BIOSCIENCES LIMITED (hereinafter referred to as “Anthem”/“Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) providing discovery biology services, synthetic chemical research and analysis, chemical synthesis, manufacturing of specialty chemical products, analytical method development, and related services.
- [Policy on Vigil Mehcanism/Whistleblower Policy for Directors and Employees](https://anthembio.com/whistle-blower-policy/): At Anthem Biosciences Limited (“the Company”), we believe in the conduct of affairs of its constituents in a fair and transparent manner by adhering to the highest standards of professionalism, honesty, integrity and ethical behavior.
- [Third Party Code](https://anthembio.com/third-party-code/): ANTHEM BIOSCIENCES LIMITED (hereinafter referred to as “Anthem”/“Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) providing discovery biology services, synthetic chemical research and analysis, chemical synthesis, manufacturing of specialty chemical products, analytical method development, and related services.
- [Human Rights Policy](https://anthembio.com/human-rights-policy/): ANTHEM BIOSCIENCES LIMITED (hereinafter referred to as “Anthem”/“Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) providing discovery biology services, synthetic chemical research and analysis, chemical synthesis, manufacturing of specialty chemical products, analytical method development, and related services.
- [Environment, Social & Governance and Climate Change Policy](https://anthembio.com/environment-social-governance-and-climate-change-policy/): ANTHEM BIOSCIENCES LIMITED (hereinafter referred to as the “Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) offering early-stage drug discovery services with its services encompassing medicinal chemistry, process chemistry, custom synthesis, discovery research and analytical R&D.
- [Corporate Social Responsibility Policy](https://anthembio.com/corporate-social-responsibility-policy/): ANTHEM BIOSCIENCES LIMITED (hereinafter referred to as the “Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) offering early-stage drug discovery services with its services encompassing medicinal chemistry, process chemistry, custom synthesis, discovery research and analytical R&D.
- [Code of Conduct](https://anthembio.com/code-of-conduct/): ANTHEM BIOSCIENCES LIMITED (hereinafter referred to as “Anthem”/“Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) providing discovery biology services, synthetic chemical research and analysis, chemical synthesis, manufacturing of specialty chemical products, analytical method development, and related services.
- [Code of Conduct for Board Members & Senior Management Personnel](https://anthembio.com/code-of-conduct-for-board-members-senior-management-personnel/): Trust, integrity, transparency, and professional service form part of the core beliefs of all activities at Anthem Biosciences Limited (‘the Company’), which has been the basis of its growth and development.
- [Code of Conduct to Regulate, Monitor and Report Trading by Employees and Other Connected Persons](https://anthembio.com/code-of-conduct-to-regulate-monitor-and-report-trading-by-employees-and-other-connected-persons/): The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (SEBI PIT Regulations) seek to govern the conduct of insiders, connected persons and persons who are deemed to be connected persons on matters relating to Insider Trading.
- [Anti-Money Laundering (AML) Policy](https://anthembio.com/anti-money-laundering-aml-policy/): ANTHEM BIOSCIENCES LIMITED (hereinafter referred to as “Anthem”/“Company”), incorporated in Bangalore on 13th June 2006 under the provisions of Companies Act, 1956, having CIN: L24233KA2006PTC039703, is a Contract Development & Manufacturing Organization (CDMO) providing discovery biology services, synthetic chemical research and analysis, chemical synthesis, manufacturing of specialty chemical products, analytical method development, and related services.
- [Large Molecules](https://anthembio.com/large-molecules/): Anthem offers a full spectrum of large molecule CDMO services, supporting clients from early discovery through to commercial manufacturing.
- [ESG, Health & Safety](https://anthembio.com/esg-health-safety/): We uphold the highest health and safety standards across our operations, ensuring a safe and sustainable work environment.
- [Digital Transformation](https://anthembio.com/digital-transformation/): At Anthem, we embrace cutting-edge digital transformation technologies to enhance our production processes, streamline operations, and ensure the highest standards of quality and compliance.
- [Anthem Advantage](https://anthembio.com/anthem-advantage/)
- [Team](https://anthembio.com/team/): Dr. Sathish Sadagopan has been with Anthem for last the 14 years, he completed his PhD from a premiere institute in India on cloning and expression of viral proteins in E coli.
- [Board of Directors](https://anthembio.com/board-of-directors/): Mr. Ajay Bhardwaj is the Chairman, Managing Director and the Chief Executive Officer of our Company.
- [Leadership](https://anthembio.com/leadership/): Ajay Bhardwaj is the Chairman, Managing Director and the Chief Executive Officer of our Company.
- [Our Partners](https://anthembio.com/our-partners/): Davos Pharma has been a leading provider of outsourcing pharmaceutical services for over 50 years.
- [Anthem Overview](https://anthembio.com/anthem-overview/)
- [Investors AV Disclaimer (DRHP)](https://anthembio.com/investors-av-disclaimer-drhp/): All persons residing outside of the United States who wish to access this video should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this video or require registration or approval for any acquisition of securities by them.
- [Investors](https://anthembio.com/investors/): Anthem Biosciences Limited (“Anthem, BSE: 544449 | NSE: ANTHEM”) (Formerly known as Anthem Biosciences Private Limited) is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”) with fully integrated operations spanning across drug discovery, development and manufacturing.
- [Investors Disclaimer](https://anthembio.com/investors-disclaimer/): Anthem Biosciences Limited does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.
- [Blog](https://anthembio.com/blog/)

## Optional

- [Agent (MCP protocol)](websites-agents.hostinger.com/anthembio.com/mcp)

[comment]: # (Generated by Hostinger Tools Plugin)